Clinical Trial Update: REO13 Melanoma With of Without GM-CSF [Phase 1, Phase 2]

View source ↗

Summary

The REO13 trial evaluating melanoma with or without GM-CSF (sargramostim) in Phase 1/2 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Skin Cancer

Drugs mentioned

• GM-CSF (granulocyte-macrophage colony-stimulating factor)

Snippet

Sponsor: University of Leeds | Conditions: Melanoma, Cancer of Skin | Phase 1, Phase 2 | Status: WITHDRAWN